XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies
Chris E. Lawrence(Xencor (United States)), David F. Carmichael(Xencor (United States)), John R. Desjarlais(Xencor (United States)), Eugene A. Zhukovsky(Xencor (United States)), Irene Leung(Xencor (United States)), Sher Karki(Xencor (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Seung Y. Chu(Xencor (United States)), Holly Horton(Xencor (United States))
Cited by 1
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403